DEVELOPMENT OF NOVEL PRECLINICAL MODELS OF SECONDARY RESISTANCE TO THE PI3KΔ INHIBITOR IDELALISIB IN SPLENIC MARGINAL ZONE LYMPHOMA (SMZL). (June 2017) - Arribas, A.J.; Gaudio, E.; Rinaldi, A.; Cascione, L.; Tarantelli, C.; Kwee, I.; Stathis, A.; Zucca, E.; Rossi, D.; Bertoni, F.